Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Following the challenges posed by the COVID-19 pandemic's transition, a leadership reorganization, a shaky foray into health care, and recent labor issues with pharmacy staff, Walgreens is now going “line by line” to see where the company could cut costs.   That's the latest from the retailer.

Walgreens Looks Aisle to Aisle to Cut Costs

Walgreens Boots Alliance NASDAQ: WBA shares are down significantly over the past two years and may fall further. The company's turnaround efforts are slowly taking hold, and the impact of COVID-19 sales continues to weigh on results.

Walgreens Boots Alliance: Value or Value Trap?

Although the revenue and EPS for Walgreens (WBA) give a sense of how its business performed in the quarter ended August 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Here's What Key Metrics Tell Us About Walgreens (WBA) Q4 Earnings

Birkenstock Holding Plc

Costco

Intel

Eli Lilly

McDonald's

Stellantis N.V. 

The Social Security cost of living adjustment (COLA), which is tied to the rate of inflation, was a whopping 8.7% this year. It is expected to be around 3.2% for 2024.

7 Stocks to Buy With Your 2024 Social Security Increase

The new CEO of Walgreens Boots Alliance will help steer a massive cost-cutting plan as the drug-store chain attempts to stop losing money and as demand from COVID related products wains.

Walgreens shares have best day since 2022

Walgreens Boots (WBA) Q4 retail revenues are impacted by macroeconomic-driven consumer pressure and lower COVID-19 OTC test kit sales.

Walgreens Boots (WBA) Q4 Earnings Miss Estimates, Margins Down

Shares of Walgreens Boots Alliance (WBA) advanced on Thursday after the biggest U.S. pharmacy chain announced a major cost-cutting program as it struggles to overcome recent challenges, including a CEO shakeup.

Walgreens Shares Surge After Saying It Will Slash Costs

Beyond Meat

JD.com

JD.com Inc (NASDAQ:JD) and Beyond Meat Inc (NASDAQ:BYND) are moving after analysts notes, while Walgreens Boots Alliance (NASDAQ:WBA) gets a lift from an upbeat earnings report.

3 Stocks Making Outsized Midday Moves

Walgreens Boots Alliance, Inc. (NASDAQ:WBA ) Q4 2023 Earnings Conference Call October 12, 2023 8:30 AM ET Company Participants Tiffany Kanaga - Vice President, Global Investor Relations Tim Wentworth - Chief Executive Officer Ginger L. Graham - Interim Chief Executive Officer Manmohan Mahajan - Interim Global Chief Financial Officer John Driscoll - President of U.S. Healthcare Rick Gates - Senior Vice President and Chief Pharmacy Officer Conference Call Participants Lisa Gill - JP Morgan Charles Rhyee - TD Cowen George Hill - Deutsche Bank Kevin Caliendo - UBS Brian Tanquilut - Jefferies Elizabeth Anderson - Evercore ISI Eric Percher - Nephron Research Operator Good morning.

Walgreens Boots Alliance, Inc. (WBA) Q4 2023 Earnings Call Transcript

Walgreens is in financial trouble and must start a new chapter with investors.

New Walgreens CEO Needs to Cut the Dividend

Growing labor pressure from pharmacy staff is just one of several challenges Tim Wentworth will have on his plate when he starts leading Walgreens.

Incoming Walgreens CEO doesn't mention walkouts as he praises pharmacy staff

Walgreens Boots Alliance (WBA) came out with quarterly earnings of $0.67 per share, missing the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.80 per share a year ago.

Walgreens Boots Alliance (WBA) Lags Q4 Earnings Estimates

Amazon

The new chief executive officer is a veteran in healthcare industry. That's where Amazon wants to make waves.

Why Walgreens New CEO Could Impact Amazon Stock

UK high street chain Boots, which is part of WalGreens Boots Alliance, has reported its tenth consecutive quarter of market share growth. Boots UK comparable pharmacy sales increased 9.9% compared with the year before, with like-for-like retail sales increased 11.7%, boosted by growth across all categories with footfall up 4%.

Boots sales jump boosted by online and skincare

Walgreens Boots Alliance Inc (NASDAQ:WBA) swung to a loss in financial 2023, following a pre-tax charge for opioid-related claims and litigation.  The Illinois, US-based retailer and parent of Walgreens and Boots UK Ltd said in the three months ended August 31, sales rose 9.2% to $35.42 billion from $32.45 billion year-on-year.

Walgreens pledges to cut costs after posting full-year loss

Shares of Walgreens Boots Alliance Inc. WBA, +0.98% took a 2.9% dive in premarket trading Thursday, after the drug store chain and health care services company missed fiscal fourth-quarter profit expectations and provided a downbeat outlook. Net losses for the quarter to Aug. 31 narrowed to $180 million, or 21 cents a share, from $415 million, or 48 cents a share, in the year-ago period.

Walgreens stock dives after adjusted profit miss and downbeat full-year outlook

Walgreens Boots Alliance on Thursday forecast a lower-than-estimated profit for financial year 2024 as the company reduces dependence on its ailing core pharmacy business to transition to an integrated healthcare service provider. The second-largest U.S. pharmacy chain operator, whose financial year ends in August, has forecast an annual adjusted profit of $3.20 to $3.50 per share, compared to analysts' average estimate of $3.72 per share, according to LSEG data.

Walgreens misses FY24 profit estimate

Walgreens Boots Alliance reported a $180 million loss in the company's fiscal fourth quarter thanks in part to “significantly lower COVID-19 vaccine and testing volumes."

Walgreens Reports $180 Million Loss Ahead Of New CEO Taking Over

DEERFIELD, Ill.--(BUSINESS WIRE)--WBA today announced financial results for the fiscal year and fourth quarter that ended Aug. 31, 2023.

Walgreens Boots Alliance Reports Fiscal Year 2023 Earnings

Walgreens Boots Alliance unveiled on Tuesday evening whom it has selected to lead the pharmacy store chain: former head of Cigna's Evernorth Tim Wentworth.

Walgreens reveals its pick for new CEO

Walgreens Boots Alliance Inc (NASDAQ: WBA) has lost a whopping 40% this year but famed investor Jim Cramer is convinced that the stock will start to recover from here on. Walgreens pharmacists recently walked off the job Earlier this week, the second-largest U.S.

Cramer recommends buying Walgreens stock despite recent walkout

Tim Wentworth is the right choice to lead Walgreens (WBA) in its transition to offering more health-care services, CNBC's Jim Cramer said Wednesday.

Jim Cramer praises Walgreens new CEO pick, says buy the stock 'perhaps aggressively'

2 Top Dividend Stocks To Watch Right Now

Walgreens (NASDAQ: WBA ) stock is a hot topic among traders on Wednesday after the company announced its new CEO. Tim Wentworth will take over as the next CEO of the pharmacy company starting on Oct. 23.

WBA Stock Alert: What to Know as Walgreens Names New CEO

Walgreens Boots Alliance said Tuesday that it has named Tim Wentworth its new CEO.

News for Walgreens Stock (WBA)